Clinical Trials
470 trialsPhase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Trishula Therapeutics, Inc.
KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
TARSARC
Institut Bergonié
VEXILLUM
Spanish Oncology Genito-Urinary Group
CONGRATS
Institut Bergonié
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
ATLANTIC
AstraZeneca
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
HonorHealth Research Institute
Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer
Ruijin Hospital
REGO-SARC
Centre Oscar Lambret
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Dana-Farber Cancer Institute
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
Ohio State University Comprehensive Cancer Center
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
METIMMOX
University Hospital, Akershus
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
University of California, San Diego
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
Boehringer Ingelheim
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC
Massachusetts General Hospital
SHIVA
Institut Curie
Cabozantinib and Pembrolizumab in Metastatic Pancreas
University of Kentucky
MK-1454-002
Merck Sharp & Dohme LLC
PRO-CARBO
Centre Francois Baclesse
Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease
University of California, San Diego
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
BioAtla, Inc.
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
BeiGene
PANTHER
Duke University
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
Regeneron Pharmaceuticals
MEDOR
Institut Bergonié
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
METALLICA
MedSIR
DEBBRAH
MedSIR
SWIPE
Bank of Cyprus Oncology Centre
MERIBEL
MedSIR
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
University of Michigan Rogel Cancer Center
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Case Comprehensive Cancer Center
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
M.D. Anderson Cancer Center
A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Massachusetts General Hospital
EBRAIN-MEL
Grupo Español Multidisciplinar de Melanoma
AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer
Mirror Biologics, Inc.
IMPACT
University of Michigan Rogel Cancer Center
AUREA
Spanish Oncology Genito-Urinary Group
VIRAGE
Theriva Biologics SL
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
Daiichi Sankyo
LoMP II
University Hospital, Ghent
Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers
Korea University Guro Hospital
PAKT
Queen Mary University of London
NT-NAP-102-1
NeoTX Therapeutics Ltd.